keyword
MENU ▼
Read by QxMD icon Read
search

High Price Drugs

keyword
https://www.readbyqxmd.com/read/30316230/an-investigation-of-prescription-indicators-and-trends-among-general-practitioners-and-specialists-from-2005-to-2015-in-kerman-iran
#1
Ali Masoud, Somayeh Noori Hekmat, Reza Dehnavieh, Naser Haj-Akbari, Atousa Poursheikhali, Zhaleh Abdi
BACKGROUND: The World Health Organization (WHO) aims to promote strategies that ensure efficacy, safety, suitability, and cost-effectiveness of medicine prescription. Health systems should design effective mechanisms to monitor prescription and rational use of medicines at all healthcare settings. This study aimed to determine and analyze prescription patterns of general practitioners and specialists in Kerman/Iran from 2005 to 2015. METHODS: This is an explanatory mixed method study...
April 25, 2018: International Journal of Health Policy and Management
https://www.readbyqxmd.com/read/30309442/rumble-over-drug-rebates-as-pharma-payers-duke-it-out
#2
Thomas Reinke
Pharma says rebates are a primary driver of high drug prices because drug companies raise prices in response to payers' demands for rebates in exchange for preferred placement on their formularies. PBMs and payers object. They say the rebates they get from drugmakers are largely passed on to health plans and patients and save consumers billions of dollars in the form of lower premiums and copays.
October 2018: Managed Care
https://www.readbyqxmd.com/read/30302848/attitudinal-and-behavioural-responses-to-increasing-tobacco-control-regulation-among-high-smoking-prevalence-groups-a-qualitative-study
#3
Ashleigh Parnell, Emily Box, Nicole Biagioni, Billie Bonevski, Juli Coffin, Terry Slevin, Julia Anwar-McHenry, Simone Pettigrew
INTRODUCTION AND AIMS: Despite substantial reductions in smoking prevalence in many countries, rates remain high among people who are experiencing disadvantage. This study aimed to explore attitudinal and behavioural responses to population-wide tobacco control policies among Australian smokers experiencing disadvantage. DESIGN AND METHODS: Semi-structured qualitative interviews were conducted with 84 smokers attending community service organisations in the mental health, homelessness, and alcohol and other drug sectors...
October 9, 2018: Drug and Alcohol Review
https://www.readbyqxmd.com/read/30288069/cost-effectiveness-analysis-of-treatment-timing-considering-the-future-entry-of-lower-cost-generics-for-hepatitis-c
#4
Katherine Heath
Background: Cost-benefit analyses are crucial to inform treatment policies, particularly when the cost of patented drugs is very high. The cost of patented drugs is the limiting factor in hepatitis C treatment. However, hepatitis C drug costs are expected to fall following patent expiration, due to generic drug introduction. Methods: An existing mathematical model by Shih et al was extended to consider lower-cost future generics in health economic models of hepatitis C...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/30286735/the-landscape-of-vaccines-in-china-history-classification-supply-and-price
#5
Yaming Zheng, Lance Rodewald, Juan Yang, Ying Qin, Mingfan Pang, Luzhao Feng, Hongjie Yu
BACKGROUND: Vaccine regulation in China meets World Health Organization standards, but China's vaccine industry and immunization program have some characteristics that differ from other countries. We described the history, classification, supply and prices of vaccines available and used in China, compared with high-and middle-incomes countries to illustrate the development of Chinese vaccine industry and immunization program. METHODS: Immunization policy documents were obtained from the State Council and the National Health and Family Planning Commission (NHFPC)...
October 4, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/30281977/challenges-and-benefits-of-repurposing-licensed-approved-cleared-products-for-a-radiation-indication
#6
Paul W Price, Andrea L DiCarlo
Increasingly, the risk of a radiological or nuclear public health emergency is a major concern for the U.S. government. To address a potential incident and ensure that the U.S. Government is prepared to respond to any civilian or military casualties that could result, the U.S. Department of Health and Human Services (HHS), together with the Department of Defense, has been charged with the development of medical countermeasures (MCMs) to treat individuals experiencing acute and delayed injuries that can result from exposure to radiation...
October 3, 2018: Radiation Research
https://www.readbyqxmd.com/read/30265063/validation-of-a-brief-behavioral-economic-assessment-of-demand-among-cigarette-smokers
#7
Liqa N Athamneh, Jeffrey S Stein, Michael Amlung, Warren K Bickel
Basic and clinical addiction research use demand measures and analysis extensively to characterize drug use motivations. Hence, obtaining an accurate and brief measurement of demand that can be easily utilized in different settings is highly valued. In the current study, 2 versions of a breakpoint measure, designed to capture cigarette demand, were investigated in 119 smokers who were recruited from an online crowdsourcing platform. The first version determines the maximum price a smoker is willing to pay for one cigarette received right now when paid out of pocket, and the second determines the maximum price when paid using a hypothetical $100 gift card received for free...
September 27, 2018: Experimental and Clinical Psychopharmacology
https://www.readbyqxmd.com/read/30238525/policy-intervention-for-access-to-medicine-does-it-work-similarly-for-poor-and-non-poor
#8
Arijita Dutta, Satarupa Bandyopadhyay
Many federal states in India have recently taken steps to improve distribution and affordability of medicines across public hospitals for reducing high out-of-pocket (OOP) expenditure. West Bengal has introduced a Public-Private Partnership (PPP) scheme, Fair Price Medicine Shops (FPMS) within government hospitals in 2012, which offers high discounts on maximum retail price of the drugs. This model introduces the state as a facilitator, rather than provider or financer, of health care. This paper attempts to measure its impact on OOP expenditure (OOPE) of patients using propensity-score-matching technique on the data collected from primary survey among patients...
September 20, 2018: International Journal of Health Planning and Management
https://www.readbyqxmd.com/read/30233363/availability-and-affordability-of-drugs-with-a-conditional-approval-by-the-european-medicines-agency-comparison-of-korea-with-other-countries-and-the-implications
#9
Hye-Young Kwon, Hyungmin Kim, Brian Godman
Introduction: There have been concerns with the availability and affordability of EMA's recently approved medicines with a conditional approval in Korea. This needs to be addressed to provide future guidance to the authorities in Korea. Objective: Compare the availability and affordability of medicines with a conditional approval by the European Medicines Agency (EMA) among 12 countries (United States, United Kingdom, France, Germany, Switzerland, Italy, Japan, Canada, Taiwan, Australia, New Zealand, and Korea) in light of access to medicine concerns in Korea...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/30231405/value-and-cost-of-myeloma-therapy
#10
S Vincent Rajkumar
Major advances have occurred in the treatment of multiple myeloma, including several new drugs that typically cost more than $100,000 per year. Although the gains in myeloma therapy improve overall survival considerably, they are available to only a fraction of the population of patients with myeloma in the world because of regulatory barriers and cost. Myeloma is an example of what is happening in cancer on a much larger scale. Many of the problems discussed call for a wider discussion across all cancers, but they are amplified in myeloma because of the need for multidrug regimens that combine three or more expensive new drugs for prolonged periods of time...
May 23, 2018: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/30227752/talking-about-hepatitis-c-faqs-from-young-adults-who-inject-drugs
#11
Lauren L Knight, Katherine Wagner, Yuridia Leyva, Veronica R Bruce, Kirsten A M White, Yvonne S Talamantes, Brittany Price, Kimberly Page, Martha L Carvour
INTRODUCTION: Young adults who inject drugs and live in rural communities are at high risk for hepatitis C virus (HCV) infection. Recent changes in HCV treatment must be communicated within these communities to improve access to care and reduce HCV transmission. METHODS: Field workers in the ¡VÁLE! Hepatitis Treatment and Integrated Prevention Services study identified frequently asked questions (FAQs) posed by young-adult participants at high risk for HCV during screening and educational sessions...
November 2018: Health Promotion Practice
https://www.readbyqxmd.com/read/30218844/rationale-and-design-of-the-evolve-short-dapt-study-to-assess-3-month-dual-antiplatelet-therapy-in-subjects-at-high-risk-for-bleeding-undergoing-percutaneous-coronary-intervention
#12
Laura Mauri, Ajay J Kirtane, Stephan Windecker, Robert W Yeh, Harold L Dauerman, Matthew J Price, Thomas Christen, Dominic J Allocco, Ian T Meredith, Dean J Kereiakes
BACKGROUND: While extended dual antiplatelet therapy (DAPT) with aspirin and a platelet (P2Y12 ) inhibitor after percutaneous coronary intervention (PCI) reduces the risk of stent thrombosis (ST) and myocardial infarction (MI), it also increases bleeding. Newer generation drug-eluting stents with bioabsorbable polymer coatings may reduce thrombotic events and allow abbreviated DAPT in selected patients. The EVOLVE Short DAPT study is designed to evaluate the safety of 3-month DAPT in high bleeding risk subjects treated with the SYNERGY bioabsorbable polymer everolimus-eluting stent...
August 17, 2018: American Heart Journal
https://www.readbyqxmd.com/read/30215707/the-availability-price-and-affordability-of-antidiabetic-drugs-in-hubei-province-china
#13
Shiwei Gong, Hongbing Cai, Yufeng Ding, Weijie Li, Xu Juan, Jinlan Peng, Si Jin
Based on the high prevalence and undiagnosed rate of diabetes mellitus in China in recent years, the aim of this work was to evaluate the availability, price and affordability of pharmacotherapy for diabetes in public hospitals in Hubei province, China. In 2016, a cross-sectional survey was conducted using World Health Organization/Health Action International (WHO/HAI) methodology. Information on the availability and prices of 20 antidiabetic drugs was collected from 34 public hospitals representing three levels of care...
October 1, 2018: Health Policy and Planning
https://www.readbyqxmd.com/read/30196515/cost-evolution-of-biological-agents-for-the-treatment-of-spondyloarthritis-in-a-tertiary-hospital-influential-factors-in-price
#14
Mariángeles González-Fernández, Elena Villamañán, Inmaculada Jiménez-Nácher, Francisco Moreno, Chamaida Plasencia, Francisco Gaya, Alicia Herrero, Alejandro Balsa
Background Spending on biological agents has risen dramatically due to the high cost of the drugs and the increased prevalence of spondyloarthritis. Objective To evaluate the annual cost per patient and cost for each biological drug for treating patients with spondyloarthritis from 2009 to 2016, and to calculate factors that affect treatment cost, such as optimizing therapies by monitoring drug serum levels, the use of biosimilar-TNF inhibitors, and official discounts or negotiated rebates in biologicals acquired by the pharmacy department...
September 8, 2018: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/30171303/-innovative-therapeutic-approaches-for-hereditary-neuromuscular-diseases
#15
REVIEW
J Kirschner, B Schoser
Advances in the understanding of the genetic mechanisms and pathophysiology of neuromuscular diseases have recently led to the development of new, innovative and often mutation-specific therapeutic approaches. Methods used include splicing modification by antisense oligonucleotides, read-through of premature stopcodons, use of viral vectors to introduce genetic information, or optimizing the effectiveness of enzyme replacement therapies. The first drugs have already been approved for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy...
October 2018: Der Nervenarzt
https://www.readbyqxmd.com/read/30160600/challenges-and-benefits-of-repurposing-products-for-use-during-a-radiation-public-health-emergency-lessons-learned-from-biological-threats-and-other-disease-treatments
#16
Andrea L DiCarlo, David R Cassatt, William E Dowling, John L Esker, Judith A Hewitt, Oxana M Selivanova, Mark S Williams, Paul W Price
The risk of a radiological or nuclear public health emergency is a major growing concern of the U.S. government. To address a potential incident and ensure that the government is prepared to respond to any subsequent civilian or military casualties, the U.S. Department of Health and Human Services and the Department of Defense have been charged with the development of medical countermeasures (MCMs) to treat the acute and delayed injuries that can result from radiation exposure. Because of the limited budgets in research and development and the high costs associated with bring promising approaches from the bench through advanced product development activities, and ultimately, to regulatory approval, the U...
August 30, 2018: Radiation Research
https://www.readbyqxmd.com/read/30160186/cost-effectiveness-analysis-of-sequential-treatment-of-abaloparatide-followed-by-alendronate-versus-teriparatide-followed-by-alendronate-in-postmenopausal-women-with-osteoporosis-in-the-united-states
#17
Quang A Le, Joel W Hay, Russell Becker, Yamei Wang
BACKGROUND: The US Food and Drug Administration has recently approved abaloparatide (ABL) for treatment of women with postmenopausal osteoporosis (PMO) at high risk of fracture. With increasing health care spending and drug prices, it is important to quantify the value of newly available treatment options for PMO. OBJECTIVE: To determine cost-effectiveness of ABL compared with teriparatide (TPTD) for treatment of women with PMO in the United States. METHODS: A discrete-event simulation (DES) model was developed to assess cost-effectiveness of ABL from the US health care perspective...
August 30, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/30150462/investigating-the-efficacy-of-triple-artemisinin-based-combination-therapies-tacts-for-treating-plasmodium-falciparum-malaria-patients-using-mathematical-modelling
#18
Saber Dini, Sophie Zaloumis, Pengxing Cao, Ric N Price, Freya J I Fowkes, Rob W van der Pluijm, James M McCaw, Julie A Simpson
The first line treatment for uncomplicated falciparum malaria is artemisinin-based combination therapy (ACT), which consists of an artemisinin derivative co-administered with a longer acting partner drug. However, the spread of Plasmodium falciparum resistant to both artemisinin and its partner drugs poses a major global threat to malaria control activities. Novel strategies are needed to retard and reverse the spread of these resistant parasites. One such strategy is triple artemisinin-based combination therapy (TACT)...
August 27, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/30146960/diagnosis-confirmation-model-a-value-based-pricing-model-for-inpatient-novel-antibiotics
#19
Ka Lum, Taimur Bhatti, Silas Holland, Mark Guthrie, Stephanie Sassman
The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics...
June 2018: Journal of Law, Medicine & Ethics: a Journal of the American Society of Law, Medicine & Ethics
https://www.readbyqxmd.com/read/30136662/approaches-to-improving-access-to-essential-cancer-medicines-in-the-who-south-east-asia-region
#20
Meenakshi V Chivukula, Klara Tisocki
The high cancer burden in the World Health Organization (WHO) South-East Asia Region represents not only a significant cause of death, disability and suffering but also a major threat to development. In 2015, the need for equitable access to cancer treatments was underscored by the addition of 16 cancer drugs to the 19th WHO model list of essential medicines, including three high-cost medicines. This paper explores strategies to improve access, including - but not limited to - managing costs through regional cooperation; coordinated procurement mechanisms; price controls; differential pricing; and licensing agreements...
September 2018: WHO South-East Asia Journal of Public Health
keyword
keyword
160259
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"